Imon Ghosh

More From Imon Ghosh


Is Shift4 Payments a Winner in the Fintech Industry?

Shares of Shift4 Payments (FOUR) have risen moderately so far this year on investors’ optimism about the fintech industry’s prospects. However, its weak financials and premium valuation remain causes for concern. This, along with the risks associated with its business operations, could result in a price decline in the near term. So, let’s take a close look at FOUR.

Does Vaxart Deserve a Place in Your Portfolio?

Vaxart (VXRT), a clinical-stage biotech company, has made advances in developing a multivariant oral COVID-19 vaccine candidate. However, given that the vaccine candidate is still undergoing Phase I and Phase 2 clinical trials at a time when VXRT’s peers have long ago launched their vaccines, is VXRT late too late to the party? Is its stock a risky bet? Read on.

Is SemiLEDS a Winning Chip Stock?

Shares of SemiLEDs (LEDS), a Taiwan-based semiconductor manufacturer, have been rallying on the rising prices of semiconductors amid a global chip shortage. However, given that the company is still not profitable, will it be able to survive and thrive in the competitive landscape? Let’s find out.

Is China Automotive Systems a Buy?

China Automotive (CAAS) saw its share price surge substantially over the past year thanks to optimism surrounding China's growing electric vehicle market and the company’s technological and product advancement. However, as a new wave of competitors threatens its market share, what are the company’s prospects? Read more to find out.

Gilead vs. Biogen: Which Biotech Stock is a Better Buy?

The biopharmaceutical sector has exhibited strong momentum in recent years, driven by government initiatives to modernize the drug regulatory pathway and higher investments in research and development. Also, the COVID-19 has proven to be a catalyst for the sector’s growth. Now that biotech innovation is perceived more clearly as critical to worldwide human health, we think top players Gilead Sciences (GILD) and Biogen (BIIB) should see sustained demand for their products to their valuation benefit. But let’s find out which of these stocks is a better buy now.

United Parcel Service Soared 15% in April: Will the Rally Continue?

Shares of United Parcel Service (UPS) rallied recently because of increasing demand for the company’s delivery and shipping services, fueled by the e-commerce boom. And because the boom in doorstep deliveries and COVID-19 vaccine shipments is likely to continue for some time, we think UPS should see a substantial improvement in its financials and a rise in its profitability. Read on.

General Motors Has Surged 37% YTD: More Upside Left?

General Motors (GM) has seen its share price surge 37.3% year-to-date, amid optimism surrounding its plans on the electric vehicle (EV) front and a substantial improvement in its sales. However, because a global semiconductor chip shortage could lead to a halt in automobile production and perhaps temporary plant closures, will the company be able to maintain its growth trajectory? Read more to find out.

Naked Brand Group vs. L Brands: Which Intimate Apparel Stock is a Better Buy?

The increased availability of diverse products in various designs, as well as growing attention to comfort and style, have fostered a reliance by consumers on popular intimate apparel players Naked Brand Group (NAKD) and L Brands (LB). We think that their internationally recognized brands and growing global footprint should help their stocks keep advancing. But let’s find out which of these stocks is a better buy now.
Entrepreneur Index

Down 5% in 2021, Will Netflix Rebound?

Shares of Netflix (NFLX) have seen their prices plunge recently because of a slowdown in subscriber growth and production delays. However, as the dominant streaming company increases its content spending significantly this year to deliver more titles to its members, the company should generate substantial user growth in the coming months. So, we think the stock should rebound quickly. Read on.

Radware vs. Proofpoint: Which Cybersecurity Stock is a Better Buy?

Unprecedented cyber criminality and increased risk exposure have driven a significant increase in cyber security spending by business enterprises. The increasing need for privacy-related solutions has fostered a strong business environment for cybersecurity providers Radware (RDWR) and Proofpoint (PFPT). But let’s find out which of these stocks is a better buy now.

Is MindMed a Good Psychedelic Stock to Buy?

A clinical-stage psychedelic medicine biotech company, Mind Medicine Inc. (MMEDF), has benefited from growing demand for therapies for people with mental disorders. However, several headwinds related to FDA approval and uncertainties surrounding its commercialization prospects could lead to a stock-price retreat. So, let’s take a closer look at this name.

Is Ideanomics a Good Electric Vehicle Stock to Add to Your Portfolio?

The commercial electric vehicle (EV) and fintech operator Ideanomics, Inc. (IDEX) has been trying to diversify its portfolio by making strategic deals. However, given its unprofitability and financial weakness, will its diversification efforts help the stock? Read on.

Splunk vs. PTC: Which Internet of Things (IoT) Stock is a Better Buy?

The Internet of Things (IoT) has become an ecosystem where analytical tools, cloud-based solutions and software are integrated to enable businesses to function efficiently. With more enterprises investing in IoT devices to deliver solutions that will power the digitally connected future, leading software companies Splunk (SPLK) and PTC (PTC) are poised to grow in the coming months. But let’s find out which of these stocks is a better buy now.

Amazon vs. Alphabet: Which FAANG Stock is a Better Buy?

Amid ballooning digital dependence worldwide, FAANG stocks have been reaping the most benefits because of their overwhelming market share. Both (AMZN) and Alphabet (GOOGL) have been advancing faster than ever due to the world’s accelerating shift from analog to digital lifestyles in recent months. But, putting the regulatory scrutiny they are both currently facing to the side for a moment, let’s find out which of these stocks is a better buy now.